Representative before the EPO

Employment test 51 - 200 employees
Company dna d young and co llp
operating since 1891
Headquarter in London and 2 offices
active in Legal Services, IP Consulting, and IP Portfolio Processing

We have observed 52 EP applications Garreth Andrew Duncan has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 16, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11765816

COMPOSITION FOR AMELIORATION OF HYPOALBUMINEMIA

IPC classification:
A23L 1/30, A61K 31/198, A61P 7/00, A61P 43/00
Applicant:
Otsuka Pharmaceutical Factory, Inc.
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
The patent has been granted
EP11806826

PANCREATIC ISLET SEPARATION METHOD, AND PROTECTIVE SOLUTION FOR PROTECTING PANCREATIC ISLET TISSUE

IPC classification:
C12N 5/071, C12N 9/50, C12N 9/99
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
The patent has been granted
EP12704898

COMPOSITE MATERIAL

IPC classification:
B01D 67/00, B01D 69/14, B01D 71/26, B01D 71/28, B01D 71/30, B01D 71/44, B01J 20/10, B01J 20/26, B01J 20/28
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
EXAMINATION REQUESTED
EP12708215

2-AMINO-NAPHTHYRIDINE DERIVATIVES

IPC classification:
A61K 31/435, A61P 35/00, C07D 471/04
Applicant:
Concert Pharmaceuticals Inc
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11706703

PYRIMIDINE DERIVATIVES

IPC classification:
A61K 31/505, A61P 31/18, C07B 59/00, C07D 239/48
Applicant:
Concert Pharmaceuticals Inc
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12779411

COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS

IPC classification:
A01N 43/54, A01N 43/66, A61K 31/505, A61K 31/53, C07D 401/00
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12738263

SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES

IPC classification:
A61K 31/437, A61P 11/00, A61P 17/00, A61P 19/00, A61P 29/00, A61P 35/00, A61P 37/00, C07D 471/04, C07D 519/00
Applicant:
Takeda Pharmaceutical Company Limited
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
PATENT GRANTED
EP12861665

METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE

IPC classification:
A61K 31/495
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION WITHDRAWN
EP12767744

METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES

IPC classification:
A61K 31/495
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION WITHDRAWN
EP12748097

TREATMENT OF TYPE 2 DIABETES WITH FTY720

IPC classification:
A61K 31/137, A61P 3/10
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
PATENT GRANTED
EP11758072

SUBSTITUTED AZAINDOLES

IPC classification:
A61K 31/435, A61P 35/00, C07D 471/04
Applicant:
Concert Pharmaceuticals Inc
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12756614

USE OF ORGANIC COMPOUND FOR THE TREATMENT OF NOONAN SYNDROME

IPC classification:
A61K 31/166, A61P 43/00
Applicant:
Novartis AG
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Agent:
Karen Dorothee Larbig, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12830938

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

IPC classification:
A01N 43/56, A61K 31/415
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13189355

Compositions for treating cancer

IPC classification:
A61K 31/5025, A61P 35/00, A61P 35/02
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13772420

INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF

IPC classification:
A01N 43/54
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
PATENT GRANTED
EP11707764

Process for the production of 2-amino-5-fluoro-thiazole

IPC classification:
C07D 277/40, C07D 277/46, C07D 277/50
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12847217

NOVEL COMPOSITION FOR GENE DELIVERY

IPC classification:
A61K 38/17
Agent:
Multiple attorneys, D Young & Co LLP
Status:
PATENT GRANTED
EP12809882

PHARMACEUTICAL FORMULATIONS

IPC classification:
A61K 9/14, A61K 9/20, A61K 9/48
Applicant:
Novartis AG
Applicant:
Array Biopharma, Inc.
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14159994

Method for producing peptide

IPC classification:
C07K 1/113, C07K 5/10, C07K 7/06, C07K 9/00, C07K 14/46, C08B 37/00
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
PATENT GRANTED
EP11701347

APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS

IPC classification:
A61K 31/437, A61P 3/10, C07D 471/04
Applicant:
Takeda Pharmaceutical Company Limited
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12771099

METHODS FOR CHRONIC PAIN MANAGEMENT AND TREATMENT USING HCG

IPC classification:
A61K 38/16, A61K 38/24, A61P 25/04
Agent:
Jochen Kilchert, Meissner Bolte & Partnerschaft mbB
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13733913

METHODS OF REDUCING RISK OF CARDIOVASCULAR DISEASE

IPC classification:
A61K 31/19, A61P 9/00
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP14175458

Dipeptidyl peptidase inhibitors

IPC classification:
A61K 31/5025, A61K 31/519, A61K 31/53, A61K 31/542, A61P 37/00, C07D 471/04, C07D 487/04, C07D 498/04, C07D 513/04
Applicant:
Takeda Pharmaceutical Company Limited
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12768941

BICYCLO[6.1.0]NON-4-YNE REAGENTS FOR CHEMICAL MODIFICATION OF OLIGONUCLEOTIDES

IPC classification:
C07D 239/22, C07F 9/02, G01N 33/531, G01N 33/68
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11776961

METHOD OF MAKING AZAINDAZOLE DERIVATIVES

IPC classification:
C07D 471/04
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14179491

Bifidobacteria for Treating myocardial infarction

IPC classification:
A61K 31/65, A61K 35/74, A61P 3/04, A61P 3/10, A61P 9/00, A61P 29/00, A61P 31/12
Applicant:
DuPont Nutrition Biosciences ApS
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Agent:
DuPont EMEA
Status:
EXAMINATION IN PROGRESS
EP12853870

PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF COGNITIVE FUNCTION DISORDERS COMPRISING SPINOSYN

IPC classification:
A61K 31/70, A61K 31/7048, A61P 25/28
Applicant:
Seoul National University Research & Development Business Foundation
Applicant:
University-Industry Cooperation Group of Kyung Hee University
Agent:
Multiple attorneys, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13176816

Fluoride ion battery compositions

IPC classification:
H01M 6/16, H01M 10/05, H01M 10/0567, H01M 10/0568, H01M 10/0569
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12716773

N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES

IPC classification:
A61K 31/5383, A61P 29/00, C07D 498/14
Applicant:
Takeda Pharmaceutical Company Limited
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13768214

PROCESS OF PREPARING SOLIFENACIN OR SALT THEREOF, AND NOVEL INTERMEDIATE USED IN THE PROCESS

IPC classification:
A61K 31/439, A61P 13/00, C07D 401/12, C07D 453/02
Agent:
Multiple attorneys, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP13782134

METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES

IPC classification:
A61K 31/165
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13788352

COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS

IPC classification:
C07D 239/48
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP11715119

NEURAMINIDASE INHIBITORS

IPC classification:
A61K 31/155, A61K 31/351, C07C 279/16, C07D 309/28
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13809531

PHARMACEUTICAL COMPOSITION CONTAINING FIMASARTAN AND HYDROCHLOROTHIAZIDE

IPC classification:
A61K 9/20, A61K 9/28, A61K 31/4184, A61K 31/4422
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP13737976

AZAINDOLE DERIVATIVES WHICH ACT AS PI3K INHIBITORS

IPC classification:
A61K 31/506, A61P 9/00, A61P 35/00, A61P 37/00, C07D 471/04, C07D 519/00
Applicant:
Takeda Pharmaceutical Company Limited
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13742568

5HT3 RECEPTOR ANTAGONISTS

IPC classification:
C07D 401/04, C07D 401/12, C07D 401/14, C07D 403/04, C07D 451/12, C07D 471/02, C07D 487/14, C07D 498/08
Applicant:
Takeda Pharmaceutical Company Limited
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP13742355

5-HT3 RECEPTOR ANTAGONISTS

IPC classification:
C07D 401/04, C07D 401/12, C07D 401/14, C07D 403/04, C07D 451/12, C07D 471/02, C07D 487/14, C07D 498/08
Applicant:
Takeda Pharmaceutical Company Limited
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP13745254

DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS

IPC classification:
A61K 31/4015, A61K 31/4025, A61P 19/08, A61P 19/10
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
PATENT GRANTED
EP13745744

DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS

IPC classification:
A61K 31/4015, A61K 31/4025, A61P 17/14, A61P 19/10, A61P 25/02, A61P 27/02, A61P 27/06, C07D 207/20, C07D 403/12
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
PATENT GRANTED
EP13750488

QUINOXALINE DERIVATIVES AS GPR6 MODULATORS

IPC classification:
A61K 31/498, A61P 25/00, C07D 241/44, C07D 471/04, C07D 487/04
Applicant:
Takeda Pharmaceutical Company Limited
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
PATENT GRANTED
EP13833473

PHARMACEUTICAL COMPOSITION CONTAINING COMPLEX EXTRACT OF AURANTII NOBILIS PERICARPIUM AND CRATAEGUS AS AN ACTIVE INGREDIENT FOR TREATING OR PREVENTING OBESITY OR LIPID-RELATED METABOLIC DISEASES

IPC classification:
A61K 36/73, A61K 36/752, A61P 3/00, A61P 3/04
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13832613

PHARMACEUTICAL COMPOSITION FOR TREATING GASTRO-OESOPHAGEAL REFLUX DISEASE

IPC classification:
A61K 9/08, A61K 9/14, A61K 9/20, A61K 9/48, A61K 31/047, A61K 31/4439, A61K 31/7016, A61K 31/702, A61K 31/7032, A61K 31/715, A61K 31/732, A61K 31/733, A61P 1/04
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
EXAMINATION REQUESTED
EP13179744

Administration of mTOR inhibitors

IPC classification:
A61K 31/436, A61P 35/00
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION WITHDRAWN
EP11709802

FUEL CELL, CATALYST AND METHODS

IPC classification:
H01M 4/86, H01M 4/92, H01M 8/10
Applicant:
University of Southampton
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11720265

DELIVERY OF CHOLESTERYL ESTER TO STEROIDOGENIC TISSUES

IPC classification:
A61K 38/45, A61P 1/16
Applicant:
MedImmune, LLC
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Agent:
AstraZeneca PLC
Agent:
Evangelia Ttofi, MedImmune Limited
Status:
EXAMINATION IN PROGRESS
EP11707760

DEUTERATED TETRAHYDRONAPHTHALENE DERIVATES

IPC classification:
A61K 31/4184, A61P 9/00, C07D 235/14
Applicant:
Concert Pharmaceuticals Inc
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11730850

COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET

IPC classification:
A61K 31/4468, A61K 31/5025, A61K 39/395, A61K 45/06, A61P 35/00
Applicant:
Takeda Pharmaceutical Company Limited
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11720264

HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS

IPC classification:
A61K 31/438, A61P 25/04, C07D 491/20, C07D 498/20
Applicant:
Vertex Pharmaceuticals Incorporated
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
PATENT GRANTED
EP11817285

DETECTION OF LCAT ACTIVITY

IPC classification:
C12Q 1/48
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12189293

Polo-like kinase inhibitors

IPC classification:
A61K 31/4545, A61P 11/00, A61P 37/08, C07D 487/04
Applicant:
Takeda Pharmaceutical Company Limited
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11833524

METHODS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS

IPC classification:
A61K 31/505, A61P 35/00
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11810759

GEMCABENE AND DERIVATIVES FOR TREATING PANCREATITIS

IPC classification:
A61K 31/194, A61P 1/18
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
PATENT GRANTED

Please Sign in to use this feature